Aimmune Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AIMT and buy or sell other stocks, ETFs, and their options commission-free!About AIMT
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system.
CEOAndrew Oxtoby, MBA
CEOAndrew Oxtoby, MBA
Employees—
Employees—
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded2011
Founded2011
Employees—
Employees—
AIMT Key Statistics
Market cap2.26B
Market cap2.26B
Price-Earnings ratio-7.68
Price-Earnings ratio-7.68
Dividend yield—
Dividend yield—
Average volume1.45M
Average volume1.45M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$37.00
52 Week high$37.00
52 Week low$10.09
52 Week low$10.09
Stock Snapshot
Aimmune Therapeutics(AIMT) stock is priced at $34.49, giving the company a market capitalization of 2.26B. It carries a P/E multiple of -7.68.
On 2025-11-14, Aimmune Therapeutics(AIMT) stock opened at —, reached a high of —, and a low of —.
Aimmune Therapeutics(AIMT) shares are trading with a volume of 0, against a daily average of 1.45M.
During the past year, Aimmune Therapeutics(AIMT) stock moved between $10.09 at its lowest and $37.00 at its peak.
During the past year, Aimmune Therapeutics(AIMT) stock moved between $10.09 at its lowest and $37.00 at its peak.
People also own
Based on the portfolios of people who own AIMT. This list is generated using Robinhood data, and it’s not a recommendation.